Summary of response in peripheral blood and bone marrow (NCIWG criteria) (n = 93)
| . | Lymphocytosis (n, %) . | Bone marrow (n, %) . | ||||
|---|---|---|---|---|---|---|
| All patients . | Responders . | Stable disease . | All patients . | Responders . | Stable disease . | |
| Patients with involvement at baseline | 783-150 | 28 | 40 | 853-151 | 31 | 44 |
| Patients evaluable at last assessment | 67 | 26 | 35 | 62 | 31 | 27 |
| Response | ||||||
| Resolved3-152 | 65 (83%) | 26 (93%) | 34 (85%) | 22 (26%) | 15 (48%) | 7 (16%) |
| ≥ 50% improved3-153 | 2 (2.6%) | 0 | 1 (2.5%) | 16 (19%) | 7 (23%) | 7 (16%) |
| Stable3-155 | 0 | 0 | 0 | 23 (27%) | 9 (29%) | 12 (27%) |
| > 50% increased3-154 | 0 | 0 | 0 | 1 (1.2%) | 0 | 1 (2.3%) |
| . | Lymphocytosis (n, %) . | Bone marrow (n, %) . | ||||
|---|---|---|---|---|---|---|
| All patients . | Responders . | Stable disease . | All patients . | Responders . | Stable disease . | |
| Patients with involvement at baseline | 783-150 | 28 | 40 | 853-151 | 31 | 44 |
| Patients evaluable at last assessment | 67 | 26 | 35 | 62 | 31 | 27 |
| Response | ||||||
| Resolved3-152 | 65 (83%) | 26 (93%) | 34 (85%) | 22 (26%) | 15 (48%) | 7 (16%) |
| ≥ 50% improved3-153 | 2 (2.6%) | 0 | 1 (2.5%) | 16 (19%) | 7 (23%) | 7 (16%) |
| Stable3-155 | 0 | 0 | 0 | 23 (27%) | 9 (29%) | 12 (27%) |
| > 50% increased3-154 | 0 | 0 | 0 | 1 (1.2%) | 0 | 1 (2.3%) |
Fifteen patients did not have lymphocytosis at baseline but had CD19+ clonal expansion in peripheral blood, were Rai stage III/IV, or both.
Determined by biopsy. Six of 7 patients with inadequate biopsies at baseline showed a predominance of malignant lymphocytes by aspirate.
Blood response defined as less than 30% lymphocytosis, bone marrow defined as normal biopsy.
Defined as 50% or greater decrease in malignant cells in blood/biopsy.
Defined as no change in malignant cells in blood/biopsy.
Defined as greater than 50% increase in malignant cells in blood/biopsy.